Provided by Tiger Trade Technology Pte. Ltd.

Verastem

8.24
+0.13001.60%
Volume:434.66K
Turnover:3.57M
Market Cap:746.24M
PE:-3.41
High:8.45
Open:8.12
Low:8.05
Close:8.11
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:1.85
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:14.93
PE(LYR):-2.73

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

TIPRANKS
·
Yesterday

Verastem Price Target Maintained with a $18.00/Share by BTIG

Dow Jones
·
Yesterday

B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating

MT Newswires Live
·
Oct 07

Verastem Inc : B. Riley Raises Target Price to $19 from $16

THOMSON REUTERS
·
Oct 07

Verastem Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Oct 06

Verastem Grants 380,500 RSUs, Issues Inducement Option for 50,000 Shares to New Hires

Reuters
·
Oct 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 05

Durable Efficacy Data in LGSOC Reinforce Verastem Franchise and Label Expansion Potential; Buy Rating Reiterated with Unchanged $18 Price Target

TIPRANKS
·
Oct 05

Verastem Price Target Maintained with a $18.00/Share by BTIG

Dow Jones
·
Oct 05

Verastem Gains on Positive Ovarian Cancer Drug Results

Reuters
·
Oct 02

Verastem announces data from analysis of Phase 2 RAMP 201 trial

TIPRANKS
·
Oct 02

Verastem Oncology Says RAMP 201 Analysis Shows 18% ORR for Avutometinib-Defactinib in Triple Wild-Type Recurrent LGSOC

Reuters
·
Oct 02

Verastem Oncology Announces New Ramp 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at Igcs 2026

THOMSON REUTERS
·
Oct 02

Verastem - Avutometinib Plus Defactinib Achieves 18% Orr, 13 Months Median Pfs in Triple Wild-Type Lgsoc

THOMSON REUTERS
·
Oct 02

Verastem - Avutometinib Plus Defactinib Achieves 44% Orr, 94% Disease Control Rate in Japanese Lgsoc Study

THOMSON REUTERS
·
Oct 02

Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal

TIPRANKS
·
Sep 29

Verastem Reports 2-Year RAMP 201 Data for Avutometinib-Defactinib Combo in Recurrent Low-Grade Serous Ovarian Cancer

Reuters
·
Sep 29

Verastem Flags RAMP 201 Biomarker Data for Late-Breaking Oral Presentation at IGCS 2026

Reuters
·
Sep 24

GenFleet Hits over 3-Week High as Cancer Drug Makes Progress on BTD List

Reuters
·
Sep 23

GenFleet Schedules Oct. 15 Investor Call to Release Preliminary Gfh375-Cetuximab Trial Data in KRAS G12D Tumors

Reuters
·
Sep 23